Trial Profile
Efficacy of bevacizumab plus temozolomide as the salvage therapy in patients with recurrent glioma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 07 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology